Effects of fluoxetine on the anticonvulsant action of valproate and ethosuximide in mouse model of myoclonic convulsions

Annals of Agricultural and Environmental Medicine

Volumn 19, Issue 3, 2012, Pages 487-490

  Borowicz, Kinga K ^a   Piskorska, Barbara ^a   Stȩpniak, Barbara ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Drug interactions; Ethosuximide; Fluoxetine; Pentylenetrazole induced seizures; Valproate

Indexed keywords

ETHOSUXIMIDE; FLUOXETINE; PENTETRAZOLE; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG POTENTIATION; IMMUNOFLUORESCENCE; LONG TERM MEMORY; MALE; MOTOR COORDINATION; MOTOR PERFORMANCE; MOUSE; MYOCLONUS EPILEPSY; MYOCLONUS SEIZURE; NONHUMAN; PASSIVE AVOIDANCE; PHARMACODYNAMICS; SEIZURE THRESHOLD;

ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; AVOIDANCE LEARNING; CONVULSANTS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; EPILEPSIES, MYOCLONIC; ETHOSUXIMIDE; FLUORESCENT ANTIBODY TECHNIQUE; FLUOXETINE; MALE; MEMORY, LONG-TERM; MICE; MOTOR ACTIVITY; PENTYLENETETRAZOLE; SEIZURES; SEROTONIN UPTAKE INHIBITORS; VALPROIC ACID;

MUS;

EID: 84866676718     PISSN: 12321966     EISSN: 18982263     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Wojszel B, Bień B. The spreading of big geriatric center in the community dwelling elderly: the challenge for the primary health care. Przeg Lek. 2002; 59: 216-221.
2. Mazarati A, Siddarth P, Baldwin RA, Shin D, Caplan R, Sankar R. Depression after status epilepticus: behavioural and biochemical deficits and effects of fluoxetine. Brain 2008; 131: 2071-2083.
3. Seethalakshmi R, Krishnamoorthy E S. Depression in epilepsy: phenomenology, diagnosis and management. Epileptic Disord. 2007; 9: 1-10.
4. Jackson M J, Turkington D. Depression and anxiety in epilepsy. J Neurol Neurosurg Psychiatry 2005; 76: 45-7.
5. Prueter C, Norra C. Mood disorders and their treatment in patients with epilepsy. J Neuropsychiatry Clin Neurosci. 2005; 17: 20-28.
6. Isbister GK, Bowe S J, Dawo A, Whyte I M. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. Clin Toxicol. 2004; 42: 277-285.
7. Hasler G, Bonwetsch R, Giovacchini G, Toczek M T, Bagic A, Luckenbaugh D A, Drevets WC, Theodore WH. 5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression. Biol Psychiatry 2007; 62: 1258-1264.
8. Merrill M A, Clough R W, Dailey J W, Jobe P C, Browning RA. Localization of the serotonergic terminal fields modulating seizures in the genetically epilepsy-prone rat. Epilepsy Res. 2007; 76: 93-102.
9. Borowicz K K, Furmanek-Karwowska K, Sawicka K, Luszczki JJ, Czuczwar S J. Chronically administered fluoxetine enhances the anticonvulsant activity of conventional antiepileptic drugs in the mouse maximal electroshock model. Eur J Pharm. 2007; 567: 77-82.
10. Borowicz K K, Ste{ogonek}pień K, Czuczwar S J. Fluoxetine enhances the anticonvulsant effects of conventional antiepileptic drugs in maximal electroshock seizures in mice. Pharm Rep. 2006; 58: 83-90.
11. Ugale R R, Mittal N, Hirani K, Chopde C T. Essentiality of central GABAergic neuroactive steroid allopregnanolone for anticonvulsant action of fluoxetine against pentylenetetrazole-inducend seizures in mice. Brain Res. 2004; 1023: 102-111.
12. Ferrero A J, Cereseto M, Reinés A, Bonavita C D, Sifonios L L, Rubio M C, Wikinski S I. Chronic treatment with fluoxetine decreases seizure threshold in naïve but not in rats exposed to the learned heplessness paradigm: Correlation with the hippocampal glutamate release. Prog Neuropsychopharmacol Biol Psychiatry 2005; 29: 678-686.
13. Zienowicz M, Wisłowska A, Lehner M, Taracha E, Skórzewska A, Maciejak P, Płaźnik A. The effect of fluoxetine in a model of chemically induced seizures-behavioral and immunocytochemical study. Neurosci Lett. 2005; 373: 226-231.
14. Boissier J R, Tardy J, Diverres J C. Une nouvelle methode simple pour explorer l'action'tranquilisante: le test de la cheminee. Med Exp. (Basel) 1960; 3: 81-84.
15. Venault P, Chapouthier G, De Carvalho L P, Simiand J, Morre M, Dodd R H, Rossier J. Benzodiazepines impair and betacarbolines enhance performance in learning and memory tasks. Nature 1986; 321: 864-866.
16. Litchfield J T, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99-113.
17. Łuszczki J J, Czuczwar S J. How significant is the difference between drug doses influencing the threshold for electroconvulsions? Pharmacol Rep. 2005; 57: 782-786.
18. Szasz B K, Mike A, Karoly R, Gerevich Z, Illes P, Vizi ES, Kiss J P. Direct inhibitory effect of fluoxetine on N-methyl-D-aspartate receptors in the central nervous system. Biol Psychiatry 2007; 62: 1303-1309.
19. Peričić D, Lazić J, Švob Štrac D. Anticonvulsant effects of acute and repeated fluoxetine treatment in unstressed and stressed mice. Brain Res 2005; 1033: 90-95.
20. Ceyhan M, Kayir H, Uzbay I T. Investigation of the effects of tianeptine and fluoxetine on pentylenetetrazole-induced seizures in rats. J Psychiatr Res. 2005; 39: 191-196.
21. Zienowicz M, Wisłowska-Stanek A, Lehner M, Taracha E, Skórzewska A, Bidziński A, Turzyńska D, Sobolewska A, Walkowiak J, Maciejak P, Szyndler J, Płaźnik A. Fluoxetine attenuates the effects of pentylenetetrazol on rat freezing behavior and c-Fos expression in the dorsomedial periaqueductal gray. Neurosci Lett. 2007; 414: 252-256.
22. Romero L, Artigas F. Preferential potentiation of the effects of serotonin uptake inhibitors by 5-HT1A receptor antagonists in the dorsal raphe pathway: role of somatodendritic autoreceptors. J Neurochem. 1997; 68: 2593-2603.
23. Deak F, Lasztoczi B, Pacher P, Petheo GL, Kecskemeti V, Spat A. Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. Neuropharmacology 2000; 39: 1029-1036.